Post-polycythemia vera myelofibrosis (PPV-MF) is a rare, chronic blood cancer that arises in 10% to 15% of patients with polycythemia vera. It is characterized by progressive bone marrow fibrosis, leading to severe anemia, splenomegaly, and systemic symptoms. According to the post polycythemia vera myelofibrosis pipeline analysis by Expert Market Research, the condition accounts for a growing segment in the myeloproliferative neoplasms market. With increasing focus on targeted therapies, drugs like Jakafi (ruxolitinib) are gaining traction. The pipeline is expected to grow significantly, driven by advancements in JAK-STAT inhibitors and novel therapeutic approaches.
Major companies involved in the post polycythemia vera myelofibrosis pipeline analysis include Celgene, Kartos Therapeutics, Inc., and others.
Leading drugs currently in the pipeline include KRT-232, PXS-5505, AJ1-11095, and others.
Increased R&D in JAK-STAT pathway inhibitors, growing focus on combination therapies, and rising clinical success rates are driving strong growth in the post polycythemia vera myelofibrosis drug pipeline.
The Post Polycythemia Vera Myelofibrosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into post polycythemia vera myelofibrosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for post polycythemia vera myelofibrosis. The post polycythemia vera myelofibrosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The post polycythemia vera myelofibrosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with post polycythemia vera myelofibrosis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to post polycythemia vera myelofibrosis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Post-polycythemia vera myelofibrosis (PPV-MF) is a rare, chronic blood cancer that develops as a progression of polycythemia vera, a type of myeloproliferative neoplasm. It occurs when the bone marrow is gradually replaced with fibrous tissue, impairing blood cell production and leading to anemia, splenomegaly, and systemic symptoms.
Post-polycythemia vera myelofibrosis treatment focuses on symptom relief and slowing disease progression. Therapeutic strategies include JAK inhibitors, transfusions, and supportive care to manage anemia, splenomegaly, and constitutional symptoms. In September 2023, the United States FDA approved Ojjaara (momelotinib) as the first and only treatment for myelofibrosis patients with anemia, including those with post-polycythemia vera myelofibrosis. This once-daily oral therapy demonstrated significant clinical benefits in the pivotal MOMENTUM trial.
Approximately 10% to 15% of patients with polycythemia vera eventually develop post-polycythemia vera myelofibrosis. According to Sarah A. ElKourashy et al., 2023, the estimated annual incidence of overt primary myelofibrosis is 0.5 to 1.5 cases per 100,000 population. As per the Drug and Health Product Portal, the estimated incidence of myelofibrosis in Canada is about 0.80 per 1,000,000 person-years. These findings highlight the importance of early diagnosis and continuous monitoring for disease progression.
This section of the report covers the analysis of post polycythemia vera myelofibrosis drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The post polycythemia vera myelofibrosis pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The report coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II (with 49%) covers a major share of the total post polycythemia vera myelofibrosis clinical trials, reflecting strong mid-stage development activity. Phase I follows with 32%, indicating a healthy influx of early-stage candidates. Phase III holds 19%, showing promising progress toward late-stage trials. This balanced pipeline supports future innovation and may significantly advance treatment options in the market.
The drug molecule categories covered under the post polycythemia vera myelofibrosis pipeline analysis include small molecules, monoclonal antibodies, immunomodulators, peptides, and RNA-based therapies. The post polycythemia vera myelofibrosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for post polycythemia vera myelofibrosis. JAK inhibitor therapies are being actively explored to manage post-polycythemia vera myelofibrosis. For instance, INCB160058, a selective small molecule targeting the JAK2V617F mutation, is currently in Phase I trials. It is under evaluation for safety and efficacy in patients with relapsed or refractory myelofibrosis, including those previously treated with JAK inhibitors but without adequate clinical response
The EMR report for the post polycythemia vera myelofibrosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed post polycythemia vera myelofibrosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in post polycythemia vera myelofibrosis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for post polycythemia vera myelofibrosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of post polycythemia vera myelofibrosis drug candidates.
KRT-232, developed by Kartos Therapeutics, Inc., is currently undergoing a Phase 2/3 study for post-polycythemia vera myelofibrosis. This oral MDM2 inhibitor is targeting TP53-wild-type patients who are relapsed or refractory to JAK inhibitors. The study is evaluating KRT-232’s safety, efficacy, and optimal dosing, aiming to establish it as a novel treatment versus best available therapy.
PXS-5505, sponsored by Syntara, is currently undergoing a Phase 1/2a clinical trial to evaluate its safety, pharmacokinetics, and pharmacodynamics in patients with primary or post-polycythemia vera myelofibrosis. This pan-lysyl oxidase inhibitor is showing promise in reversing bone marrow fibrosis. The study is including monotherapy and add-on phases with stable ruxolitinib treatment.
AJ1-11095, developed by Ajax Therapeutics in collaboration with Schrödinger, is an oral, Type II JAK2 inhibitor targeting patients with PMF, PPV-MF, or PET-MF who have failed Type I JAK2 inhibitor therapy. This ongoing Phase 1 study is evaluating its safety, tolerability, pharmacokinetics, and biomarker responses to determine the recommended Phase 2 dose for further development
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Post Polycythemia Vera Myelofibrosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for post polycythemia vera myelofibrosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into post polycythemia vera myelofibrosis collaborations, regulatory environments, and potential growth opportunities.
Myelofibrosis Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share